Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$103.7M
- Total assets
- $476.2M
- Market cap
- $2.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $119.7M
- Operating income
- -$119.7M
- Income tax
- $0
- Net income
- -$103.7M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $476.2M
- Current assets
- $474.9M
- Total liabilities
- $16.6M
- Current liabilities
- $16.6M
- Shareholders’ equity
- $459.6M
Cash flow
- Operating cash flow
- -$70.3M
- Investing cash flow
- -$173.8M
- Financing cash flow
- $218.9M
- Net cash flow
- -$25.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.1B
- EPS (diluted)
- $-1.83
- Shares outstanding
- 39.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 24, 2023
Enliven Therapeutics, Inc. (ELVN) Stock Price
- Reported a net loss of $103.7M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Enliven Therapeutics, Inc..
Write a review
News about Enliven Therapeutics, Inc.
News & sentiment via Polygon.io
Enliven Therapeutics, Inc.: frequently asked questions
Is Enliven Therapeutics, Inc. an American company?
Enliven Therapeutics, Inc. is a US-based company headquartered in Boulder, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, United States.
Is Enliven Therapeutics, Inc. publicly traded?
Yes — Enliven Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ELVN on the NASDAQ.
What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
